Black Friday Sale! Save huge on InvestingProGet up to 60% off

Witnesses in Shkreli case worried about retaliation: U.S. prosecutors

Published 02/19/2016, 01:46 PM
Updated 02/19/2016, 01:50 PM
© Reuters. Martin Shkreli, former CEO of Turing Pharmaceuticals LLC, prepares to testify before a House Oversight and Government Reform hearing on "Developments in the Prescription Drug Market Oversight" on Capitol Hill in Washington
TVTX
-

By Nate Raymond

NEW YORK (Reuters) - U.S. prosecutors said several witnesses in the criminal securities fraud case against notorious former pharmaceutical executive Martin Shkreli are concerned about retaliation and have received threats from him in the past.

Prosecutors cited the concern about witness intimidation in a brief filed late on Thursday in federal court in Brooklyn, New York, as they sought to delay a related U.S. Securities and Exchange Commission lawsuit.

The brief opposed a bid by Shkreli, 32, to take depositions and to obtain evidence in the SEC's civil case, saying doing so would result in the early disclosure of information not normally available to defendants until late stages in criminal cases.

Among the reasons for putting the SEC case on hold, prosecutors said, was the "well-founded concern of witness intimidation based on defendant Shkreli's past behavior."

Shkreli's lawyer, Benjamin Brafman, called those arguments "preposterous."

"While his keen 'intellect' can at times be intimidating to mere mortals, nothing else about (Shkreli) is intimidating at all," Brafman said in an email on Friday.

Shkreli, who gained notoriety as the head of Turing Pharmaceuticals when it raised the price of a drug to treat a parasitic infection to $750 from $13.50, was indicted in December and sued at the same time by the SEC.

Both cases allege Shkreli engaged in a Ponzi-like scheme, defrauding investors in his hedge fund MSMB Capital Management and misappropriating $11 million in assets from Retrophin Inc (O:RTRX), where he was then chief executive, to repay them.

Shkreli has pleaded not guilty and denied wrongdoing.

In Thursday's brief, prosecutors cited evidence that Shkreli, 32, "has taken steps to intimidate or threaten individuals in the past," including by engaging in a "campaign of harassment" against a former Retrophin employee in 2013.

Several witnesses cited Shkreli's harassment of that employee as the reason they believe he may retaliate against them, prosecutors said. Several also said Shkreli has previously threatened them in personal and business disputes, prosecutors wrote.

© Reuters. Martin Shkreli, former CEO of Turing Pharmaceuticals LLC, prepares to testify before a House Oversight and Government Reform hearing on "Developments in the Prescription Drug Market Oversight" on Capitol Hill in Washington

At least one witness told authorities that Shkreli, in early 2015 while knowing he was under criminal investigation, reached out to him or her "and suggested that the witness agree to a false version of certain events," prosecutors wrote.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.